Pneumosepsis. Other sepsis
Conditions
Interventions
Intervention 1: Intervention Group: Administration of Pure Hydroxocobalamin (99% purity, manufactured by the hypothetical "Dayan Teb Iranian" Pharmaceutical Company) in a final dose of 2 grams (two 1-
Sponsors
Kashan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age >18 years old Sofa score >3 score
Exclusion criteria
Exclusion criteria: Pregnancy Known history of allergy to Cobalamin Clinical diagnosis of pneumosepsis based on expert opinion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in the SOFA (Sequential Organ Failure Assessment) score in patients, from baseline to day seven. Timepoint: Measurement at baseline and subsequently at 72 hours and 7 days after the initiation of the intervention. Method of measurement: Measurement based on standard SOFA checklists through review of clinical signs and laboratory results (including PaO2/FiO2 ratio, creatinine, bilirubin, and platelets). | — |
Secondary
| Measure | Time frame |
|---|---|
| Total duration of the patient's stay (measured in days). Timepoint: Recording from the time of study entry until discharge from the hospital or patient death. Method of measurement: Based on information on patient's document and admission and discharge/death of the patient. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHamed Jelodarian
Kashan University of Medical Sciences
Outcome results
None listed